SCHEMBL6777033

SCHEMBL6777033

N=C(N)Nc1cc(C(=O)NCC(=O)NC(CC(=O)O)c2cccnc2)cc2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 14/20 0.52
ITGA2B P08514 11/20 0.52
ITGAV P06756 4/20 0.46
MDM4 O15151 1/20 0.46
ITGB1 P05556 1/20 0.46
ITGA5 P08648 1/20 0.46
MDM2 Q00987 1/20 0.46
SUCNR1 Q9BXA5 2/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
EGLN2 Q96KS0 2/20 0.40
EGLN1 Q9GZT9 2/20 0.40
LMNA P02545 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ITGB5 P18084 1/20 0.38
ITGB6 P18564 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6777998 0.86 ITGB3 (0.51) ITGB3ITGA2BITGAVMDM4ITGB1
SCHEMBL6779902 0.84 ITGB3 (0.56) ITGB3ITGA2BITGAVMDM4ITGB1
SCHEMBL6773791 0.83 ITGB3 (0.57) ITGB3ITGA2BITGAVITGB1ITGA5
SCHEMBL6776653 0.82 ITGB3 (0.58) ITGB3ITGA2BITGAVITGB1ITGA5
SCHEMBL6777910 0.80 ITGB3 (0.52) ITGB3ITGA2BITGAVMDM4ITGB1
SCHEMBL7141461 0.78 ITGB3 (0.54) ITGB3ITGA2BITGAVSUCNR1
SCHEMBL7138669 0.78 ITGB3 (0.54) ITGB3ITGA2BITGAVSUCNR1
SCHEMBL6778673 0.77 ITGB3 (0.53) ITGB3ITGA2BITGAVITGB1ITGA5
SCHEMBL6780209 0.77 ITGB3 (0.55) ITGB3ITGA2BITGAVMDM4ITGB1
SCHEMBL29391928 0.77 ITGB3 (0.55) ITGB3ITGA2BITGAVMDM4ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed